Abstract:Colony-stimulating factor-1 (CSF-1) is the primary regulator of mononuclear phagocytic cells. CSF-1 plays an important role in recruiting macrophages to tumor environment. Overexpression of CSF-1 and its ligand, colony-stimulating factor-1 receptor (CSF-1R), have been reported to be associated with the development of various types of cancers, such as breast, ovarian, and colorectal cancer. This study aims to investigate the treatment effects of a new CSF-1R inhibitor named C019199 in murine breast cancer (BC) models when administered alone or in combination with anti-PD-1 antibody. Inhibition of CSF-1R was investigated in the murine bone marrow derived macrophages (BMDMs) for cell-based assay. Furthermore, the immunocompetent Balb/c mice were subcutaneously implanted 4T1 breast cancer cells in the right flank. Mice were randomized into groups of 9 and treated with C019199 (orally, 30 mg, 60mg or 120 mg/kg/d), either alone or in combination with anti-mouse PD-1 antibody (intraperitoneally, 10 mg/kg). 1 of 9 groups was treated with single-agent Docetaxel (intraperitoneally, 10 mg/kg). The animal body weight and tumor growth were monitored twice a week. Results were analyzed by 2-way ANOVA with Bonferroni's test. 1. C019199 inhibited the murine colony-stimulating factor-1 receptor (CSF-1R) with an IC50 of about 8.0nM in cell-based assay. 2. C019199 inhibited tumor growth in murine BC models. The combination of C019199 and anti-PD-1 had better synergistic antitumor efficacy than single-agent. Balb/c mice implanted 4T1 cells were treated with C019199 alone or combined with anti-PD1 for 14 days. The antitumor efficacy and treatment detail (Table) were detected.Table: 39PEffect of C019199 on body weight and tumor size in murine 4T1 breast cancer modelsGroupAdministration regimenTumor size (mm3,Mean±SEM)Rate% of average body weight changeDay 0Day 14VehicleQD x 1467.11 ± 3.011705.69 ± 130.9613.76%Anti-mPD-1Day 0, 3, 7, 1066.82 ± 3.051343.55 ± 118.6516.43%DocetaxelDay 0, 766.88 ± 3.111023.00 ± 68.19****4.21%C019199QD x 1467.07 ± 3.171074.32 ± 59.31****11.01%C019199QD x 1466.76 ± 3.05927.24 ± 65.68****7.97%C019199QD x 1466.69 ± 2.99671.71 ± 62.56****2.18%Anti-mPD-1Day 0, 3, 7, 1066.62 ± 2.941079.65 ± 64.05****13.25%C019199QD x 14Anti-mPD-1Day 0, 3, 7, 1066.53 ± 2.86794.21 ± 105.82****10.50%C019199QD x 14Anti-mPD-1Day 0, 3, 7, 1066.41 ± 2.72619.62 ± 25.10****4.85%C019199QD x 14*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared with vehicle group. SEM, standard error of mean. Open table in a new tab *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared with vehicle group. SEM, standard error of mean. C019199 is a new tyrosine kinase inhibitor of CSF-1R. Single-agent C019199 showed dose-dependently inhibition in murine 4T1 BC tumors. C019199 combined with anti-PD-1 had better antitumor efficacy than C019199 alone. Assessed by animal body weight, such combination therapy was well tolerated. The mechanisms of C019199-mediated immunomodulatory effects in combination with anti-PD-1 need further exploration.

A CARM1 Inhibitor Potently Suppresses Breast Cancer Both In Vitro and In Vivo

Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1

Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy

Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases

Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy

Research Progress on CARM1 and its Relationship with Colorectal Cancer

CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma

A Chemical Probe of CARM1 Alters Epigenetic Plasticity Against Breast Cancer Cell Invasion

Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities

Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders

CARM1 hypermethylates the NuRD chromatin remodeling complex to promote cell cycle gene expression and breast cancer development

39P CSF-1R Inhibitor (C019199) Enhances Antitumor Effect in Combination with Anti-Pd-1 Therapy on Murine Breast Cancer Models

The emerging role of CARM1 in cancer

CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis

CARMIL1-AA selectively inhibits macropinocytosis while sparing autophagy

Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents

USP4/CARM1 Axis Promotes the Malignant Transformation of Breast Cancer Cells by Upregulating SLC7A11 Expression

Targeting fatty acid reprogramming suppresses CARM1-expressing ovarian cancer

Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca2+/Calmodulin-Dependent Protein Kinase Ii